Profile data is unavailable for this security.
About the company
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2004
- Employees9.00
- LocationAkari Therapeutics PLC22 BOSTON WHARF ROAD, FL 7BOSTON 02210United StatesUSA
- Phone+1 (646) 350-0702
- Fax+1 (646) 843-9352
- Websitehttps://www.akaritx.com/
Mergers & acquisitions
Acquired company | AKTX:NAQ since announced | Transaction value |
---|---|---|
Peak Bio Inc | 41.41% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Surrozen Inc | 0.00 | -37.58m | 35.15m | 42.00 | -- | 0.7684 | -- | -- | -18.44 | -18.44 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -67.75 | -- | -77.52 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
IN8BIO, Inc. | 0.00 | -31.04m | 35.23m | 31.00 | -- | 1.97 | -- | -- | -0.9154 | -0.9154 | 0.00 | 0.4049 | 0.00 | -- | -- | 0.00 | -123.61 | -74.18 | -145.63 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0556 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
Mink Therapeutics Inc | 0.00 | -20.59m | 35.49m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
Carmell Corp | 0.00 | -18.29m | 36.22m | 9.00 | -- | -- | -- | -- | -1.58 | -1.49 | 0.00 | -0.0719 | 0.00 | -- | -- | 0.00 | -428.46 | -- | -- | -- | 58.60 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
Curis Inc | 9.81m | -47.73m | 36.84m | 48.00 | -- | 3.89 | -- | 3.75 | -8.68 | -8.68 | 1.77 | 1.61 | 0.1253 | -- | 4.39 | 204,416.70 | -60.97 | -37.25 | -69.58 | -41.12 | 97.60 | 96.05 | -486.45 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
Aeon Biopharma Inc | 0.00 | -485.01m | 37.58m | 10.00 | -- | -- | -- | -- | -13.04 | -13.04 | 0.00 | -5.20 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -27.67 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
Angion Biomedica Corp | 0.00 | -38.99m | 37.79m | 32.00 | -- | 7.72 | -- | -- | -6.63 | -6.63 | 0.00 | 0.4765 | 0.00 | -- | -- | 0.00 | -117.72 | -105.91 | -133.85 | -331.69 | -- | -- | -- | -712.81 | -- | -- | 0.00 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
Atara Biotherapeutics Inc | 34.70m | -233.11m | 37.81m | 173.00 | -- | -- | -- | 1.09 | -52.93 | -52.93 | 7.54 | -20.43 | 0.1485 | 0.9947 | 1.92 | 154,240.00 | -99.76 | -70.20 | -213.09 | -86.94 | 69.30 | -- | -671.70 | -1,559.33 | 0.50 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
Akari Therapeutics PLC (ADR) | -100.00bn | -100.00bn | 38.03m | 9.00 | -- | -- | -- | -- | -- | -- | -- | -0.4449 | -- | -- | -- | -- | -- | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 43.61 | -- | -- | -- |
Ocean Biomedical Holdings Inc | 0.00 | -45.58m | 38.11m | 9.00 | -- | -- | -- | -- | -1.40 | -1.40 | 0.00 | -0.0642 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -612.50 | -- | -- | -- |
Vaxxinity Inc | 0.00 | -56.94m | 39.30m | 57.00 | -- | 2.93 | -- | -- | -0.4499 | -0.4499 | 0.00 | 0.1058 | 0.00 | -- | -- | 0.00 | -75.56 | -- | -111.46 | -- | -- | -- | -- | -- | -- | -- | 0.5308 | -- | -- | -- | 24.31 | -- | -- | -- |
DURECT Corp | 8.32m | -23.28m | 39.73m | 48.00 | -- | 4.79 | -- | 4.77 | -0.8653 | -0.8653 | 0.2976 | 0.2674 | 0.176 | 0.7021 | 6.87 | 143,465.50 | -49.23 | -37.34 | -167.81 | -53.44 | 80.56 | 91.83 | -279.77 | -139.11 | 0.9575 | -47.70 | 0.6377 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
Matinas BioPharma Holdings Inc | 0.00 | -23.25m | 40.18m | 32.00 | -- | 2.39 | -- | -- | -0.107 | -0.107 | 0.00 | 0.0669 | 0.00 | -- | -- | 0.00 | -80.36 | -44.62 | -86.16 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.0014 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
BioXcel Therapeutics Inc | 1.76m | -153.05m | 40.53m | 74.00 | -- | -- | -- | 23.08 | -5.18 | -5.18 | 0.0591 | -2.15 | 0.0134 | 0.6067 | 5.31 | 23,729.73 | -116.64 | -74.57 | -151.39 | -84.06 | 24.15 | -- | -8,715.72 | -32,300.74 | 2.49 | -15.67 | 3.47 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
OncoCyte Corp | 1.38m | -40.66m | 40.90m | 43.00 | -- | 2.18 | -- | 29.59 | -4.94 | -4.94 | 0.1682 | 2.05 | 0.018 | -- | 1.34 | 32,139.54 | -51.95 | -35.11 | -58.73 | -39.71 | 22.07 | -- | -2,890.23 | -2,373.36 | -- | -157.69 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Estrella Immunopharma Inc | 0.00 | -2.16m | 41.65m | -- | -- | 4.00 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Omnia Family Wealth LLCas of 31 Mar 2024 | 87.63k | 1.11% |
Sabby Management LLCas of 31 Mar 2024 | 48.49k | 0.61% |
Cerity Partners LLCas of 31 Mar 2024 | 23.64k | 0.30% |
Renaissance Technologies LLCas of 31 Mar 2024 | 14.77k | 0.19% |
BG Fund Management Luxembourg SAas of 31 Dec 2023 | 6.11k | 0.08% |
Bank of America, NA (Private Banking)as of 31 Mar 2024 | 150.00 | 0.00% |
Truvestments Capital LLCas of 31 Mar 2024 | 50.00 | 0.00% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 6.00 | 0.00% |
Cornerstone Planning Group LLCas of 31 Mar 2024 | 5.00 | 0.00% |
Tower Research Capital LLCas of 31 Mar 2024 | 0.00 | 0.00% |